Paper Details

  1. Home
  2. Paper Details

Neurokinin 3 receptor antagonism for menopausal hot flashes.

Author: ComninosAlexander N, DhilloWaljit S

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Menopausal hot flashes are a common and debilitating symptom. This article discusses the development of fezolinetant, a novel non-hormonal treatment for menopausal hot flashes. Fezolinetant is a NK3 receptor antagonist, which has recently been approved by the FDA.
Paper Details　
Original Abstract of the Article :
Menopausal hot flashes are common and debilitating. Menopausal Hormone Therapy (MHT) is effective for hot flashes but has risks and side effects that limit its use. NK3 receptor antagonism has emerged as a novel therapeutic strategy, leading to the recent FDA approval of fezolinetant, a first-in-cla...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.cell.2023.07.011

データ提供：米国国立医学図書館（NLM）

Neurokinin 3 Receptor Antagonism: A New Frontier in Menopausal Hot Flash Treatment

The [menopause] is a natural transition in a woman's life, often accompanied by [hot flashes], a common and sometimes debilitating symptom. This article explores the potential of [neurokinin 3 (NK3) receptor antagonism] as a novel approach to treating menopausal hot flashes, highlighting the recent FDA approval of [fezolinetant] as the first non-hormonal treatment for this condition.

Fezolinetant: A Non-Hormonal Treatment for Menopausal Hot Flashes

This article highlights the exciting development of fezolinetant, a first-in-class non-hormonal treatment for menopausal hot flashes. The FDA approval of this drug signifies a breakthrough in addressing a common and often distressing symptom of menopause. Imagine a refreshing desert breeze providing relief from the scorching heat, representing the potential of fezolinetant to alleviate the discomfort of menopausal hot flashes. This article underscores the importance of ongoing research and development in finding effective and safe treatments for women experiencing this common health concern.

Navigating the Treatment Landscape of Menopausal Hot Flashes

This article emphasizes the importance of a multidisciplinary approach to managing menopausal symptoms, considering both traditional and innovative treatment options. Women experiencing hot flashes should discuss their options with their healthcare providers to find the most appropriate treatment plan for their individual needs and preferences. Just as a camel adapts its route through the desert to avoid treacherous terrain, women facing menopausal challenges need personalized care to find the best path to well-being.

Dr. Camel's Conclusion

This article sheds light on the exciting advancements in the treatment of menopausal hot flashes. The development of fezolinetant offers a promising non-hormonal alternative for women seeking relief from this common symptom, paving the way for improved well-being and quality of life during this important transition.

Date :
  1. Date Completed 2023-08-08
  2. Date Revised 2023-08-08
Further Info :

Pubmed ID

37541194

DOI: Digital Object Identifier

10.1016/j.cell.2023.07.011

Related Literature

Article Analysis
・Effects of fezolinetant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.